GL1X · GenesisL1 explorer

MolNFT v1 · #32685 · protein

Design and discovery of novel, potent thrombin inhibitors with a solubilizing cationic P1-P2-linker

2BXT · Alpha thrombin: “Design and discovery of novel, potent thrombin inhibitors with a solubilizing cationic P1-P2-linker”. X-ray diffraction, 1 ligand (C2D), 3 pockets (best druggability 0.54). MolNFT v1 #32685 on GenesisL1: 3D…

PDB
2BXT
Type
protein
Length
289 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Alpha thrombin; Hirudin variant-2
EC
3.4.21.5
UniProt
P00734, P09945
Ligands
C2D
Pockets
3 · best druggability 0.54

Structure

x-ray diffraction · 3 distinct chains · 18% helix, 30% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
HAlpha thrombin (EC 3.4.21.5)protein25116% helix, 35% strandP00734
IHirudin variant-2protein1127% helix, 0% strandP09945
LAlpha thrombin (EC 3.4.21.5)protein2737% helix, 0% strandP00734

Ligands and binding sites

  • C2D · 6-chloro-1-(2-{[(5-chloro-1-benzothien-3-yl)methyl]amino}ethyl)-3-[(2-pyridin-2-ylethyl)amino]-1,4-dihydropyrazin-2-ol · ligand · chains H

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11590.540.8023C2D
2790.360.7618empty
3550.300.7617empty

Interfaces

2 interfaces between chains.

  • H–L · 1103 Ų buried · 28 hydrogen bonds · protein-protein
  • H–I · 654 Ų buried · 7 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide, 1 modified (disulfide, sulfation).

Compared structures

  • 2BXT · Design and Discovery of Novel, Potent Thrombin Inhibitors with a Solubilizing Cationic… · the same entry in another collection · chain H against H, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.